Daily Stock Analysis, IPCI, Intellipharmaceutics International Inc, priceseries

Intellipharmaceutics International Inc. Daily Stock Analysis
Stock Information
Open
0.35
Close
0.33
High
0.36
Low
0.31
Previous Close
0.35
Daily Price Gain
-0.02
YTD High
0.39
YTD High Date
Feb 8, 2019
YTD Low
0.23
YTD Low Date
Jan 2, 2019
YTD Price Change
0.07
YTD Gain
26.96%
52 Week High
7.90
52 Week High Date
Feb 15, 2018
52 Week Low
0.20
52 Week Low Date
Dec 13, 2018
52 Week Price Change
-7.37
52 Week Gain
-95.76%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jul 7. 2017
23.90
Jul 20. 2017
26.56
9 Trading Days
11.14%
Link
LONG
Jun 8. 2018
4.22
Jun 19. 2018
4.53
7 Trading Days
7.30%
Link
Company Information
Stock Symbol
IPCI
Exchange
NasdaqCM
Company URL
http://www.intellipharmaceutics.com
Company Phone
416-798-3001
CEO
Isa Odidi
Headquarters
Ontario
Business Address
30 WORCESTER ROAD, TORONTO, CANADA M9W 5X2
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Delivery
CIK
0001474835
About

Intellipharmaceutics International, Inc. is a pharmaceutical company, which engages in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of existing and new pharmaceuticals in the areas of neurology, cardiovascular, gastrointestinal tract, diabetes and pain. The company was founded on October 22, 2009 and is headquartered in Toronto, Canada.

Description

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada. It develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company's lead product is Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for attention deficit hyperactivity disorders. It also develops Rexista Oxycodone, an abuse and alcohol-deterrent controlled-release oral formulation for the relief of pain; Regabatin XR and Lyrica pregabalin extended-release capsules for the management of neuropathic pain; Effexor XR, an extended-release capsule for oral administration to treat depression; and Protonix, a delayed-release capsule for oral administration to treat gastroesophageal reflux disease. In addition, the company offers Glucophage XR, an oral antihyperglycemia drug to treat type 2 diabetes; Seroquel XR, an oral psychotropic agent for the treatment of schizophrenia, bipolar disorder, and major depressive disorder; Lamictal XR, an anticonvulsant drug to terat epilepsy; Keppra XR, an antiepileptic drug for the treatment of partial onset seizures in patients with epilepsy; and Pristiq, a selective serotonin and norepinephrine reuptake inhibitor to treat major depressive disorder. Further, it provides Oleptro, a trazodone hydrochloride extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Ranexa, a ranolazine extended release tablet for chronic angina. Intellipharmaceutics International Inc. has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.